1 / 12

The APEX AMI Investigators Published in JAMA January 3, 2007

Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. The APEX AMI Investigators Published in JAMA

phailin-suttikul
Télécharger la présentation

The APEX AMI Investigators Published in JAMA January 3, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention The APEX AMI Investigators Published in JAMA January 3, 2007

  2. APEX AMI Trial: Background • Complement is known to be both activated and a potential mediator of inflammation following reperfusion / reperfusion injury. • The goal of this trial was to evaluate the effectiveness of pexelizumab, a humanized monoclonal antibody that binds the C5 component of complement, as an adjunct to PCI in improving 30 day mortality from STEMI. Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  3. APEX AMI Trial: Study Design 5745 patients > 18 yrs with acute MI within 6 hours of symptom onset; high-risk anterior lateral or inferior MI; planned primary PCI; or new left-bundle branch block excluding those with prior fibrinolytic therapy for treatment of the index MI; complement deficiency; pregnant; breast-feeding; isolated, low-risk, inferior wall MI Prospective. Double-Blind. Placebo-Controlled. Randomized. Mean follow-up 90 days. 23% female, mean age 61 years, mean follow-up 90 days. R Placebo 2 mg/kg bolus + 0.05 mg/kg/hr for 24 hours n=2885 Pexelizumab 2mg/kg bolus + 0.05 mg/kg/hr for 24 hours n=2860 90 days follow-up • Primary Endpoint: All-cause mortality through 30 days. • Secondary Endpoint: Death at day 90 and the composite of death, cardiogenic shock, or congestive heart failure through days 30 or 90. Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  4. APEX AMI Trial: Baseline Characteristics Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  5. APEX AMI Trial: Baseline Characteristics (cont.) Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  6. APEX AMI Trial: Primary Endpoint Primary endpoint of 30 day mortality • There was no difference in the primary endpoint (mortality at 30 days) between placebo and pexelizumab (3.9% vs 4.1% respectively), ie, each experiencing a low mortality. p = 0.78 % patients Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  7. APEX AMI Trial: Secondary Endpoint Secondary composite endpoint of death, cardiogenic shock, or heart failure at 30 days p = 0.81 • The 30 day composite endpoing of death, cardiogenic shock, or congestive heart failure was similar between treatment groups (9.2% for placebo vs. 9.0% for pexelizumab). % Patients Placebo Pexelizumab Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  8. APEX AMI Trial: Secondary Endpoint (cont.) Secondary endpoint of mortality at 90 days p = NS • The secondary endpoint of mortality at 90 days remained low and was similar between both treatment groups (4.5% for placebo vs. 4.9% for pexelizumab). % Patients Placebo Pexelizumab Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  9. APEX AMI Trial: Secondary Endpoint (cont.) Secondary composite endpoint of death, shock, or heart failure at 90 days p = 0.91 • The secondary composite endpoint of death, shock, or heart failure at day 90 was similar between both treatment groups (10.2% for placebo vs. 10.2% for pexelizumab). % Patients Placebo Pexelizumab Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  10. APEX AMI Trial: Sepsis Sepsis among treatment groups • In spite of the theoretical possibility of more infection with a complement inhibitor, sepsis, while uncommon in both groups, tended to be less common in patients treated with pexelizumab than with placebo (0.56 % vs. 0.90%; respectively, p=0.13) p = 0.13 % Patients Placebo Pexelizumab Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  11. APEX AMI Trial: Summary • Among patients with ST elevation MI undergoing primary PCI, treatment with pexelizumab was not associated with a difference in mortality at 30 days compared with placebo. • Prior data from the COMMA study demonstrated a reduction in mortality at 6 months with pexelizumab compared with placebo in patients treated with primary PCI; however, the COMMA trial was designed specifically to address infarct size, not mortality at 30 days. Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

  12. APEX AMI Trial: Summary (cont.) • In addition to the present study, the PRIMO-CABG II trial also showed no significant benefit on death or MI with pexelizumab in the setting of bypass surgery. • Performance of PCI and bypass surgery can cause reperfusion injury and increase inflammation, which this compound was designed to inhibit. • Limited success has been reported to date for therapies that target reperfusion injury, although other agents are currently being investigated. Armstrong et al., JAMA. 2007 Jan; 297(1):43 - 51.

More Related